1. The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: a review

   • Abraham Goldin
   • John M. Venditti
   • Ruth Geran

   Preclinical Review Pages: 3 - 21

2. Additive cytotoxicity of adriamycin and a naturally occurring growth inhibitor extracted from bovine aorta

   • Max Haid
   • Justin Cohen
   • Jeanne D. Travis

   Preclinical Studies Pages: 23 - 29

3. Effect of inhibition of γ-glutamyltranspeptidase by AT-125 (Acivicin) on glutathione and cysteine levels in rat brain and plasma

   • Kristina E. Hill
   • Daniel D. Von Hoff
   • Raymond F. Burk

   Preclinical Studies Pages: 31 - 34

4. Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor

   • Daniel S. Zaharko
   • Joseph M. Covey
   • James A. Kelley

   Pharmacology Studies Pages: 35 - 41

5. Stability of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ; NSC 224070) in aqueous solutions by high-performance liquid chromatography

   • Andrew G. Bosanquet
   • Sheila B. McLoughlin

   Pharmacology Studies Pages: 43 - 50

6. Radioimmunoassay for mitoxantrone, a new antitumor agent

   • G. Nicolau
   • V. Szucs-Myers
   • A. Lanzilotti

   Pharmacology Studies Pages: 51 - 56

7. Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule

   • William J. Moriconi
   • Sarah Taylor
   • Barth Hoogstraten

   Clinical Trials Pages: 57 - 62

8. Epirubicin in colorectal cancer

   • Eduard E. Holdener
   • Heine H. Hansen
   • Marcel Rozencweig

   Clinical Trials Pages: 63 - 66

9. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma

   • Sarah A. Taylor
   • Bill T. Tranum
   • John J. Costanzi

   Clinical Trials Pages: 67 - 69

10. Trimetrexate: a new antifol entering clinical trials

    • Peter J. O'Dwyer
    • D. Dale Shoemaker
    • B. Leyland-Jones

    Clinical Trials Pages: 71 - 75